GPR142 (G protein receptor 142) is a novel orphan GPCR (G protein coupled receptor) belonging to ‘Class A’ of GPCR family and expressed in beta cells of pancreas. In this study, we reported the structure based virtual screening to identify the hit compounds which can be developed as leads for potential agonists. The results were validated through induced fit docking, pharmacophore modeling and system biology approaches. Since, there is no solved crystal structure of GPR142, we attempted to predict the 3D structure followed by validation and then identification of active site using threading and ab initio methods. Also, structure based virtual screening was performed against a total of 1171519 compounds from different libraries and only top 20 best hit compounds were screened and analyzed. Moreover, the biochemical pathway of GPR142 complex with screened compound2 was also designed and compared with experimental data. Interestingly, compound2 showed an increase in insulin production via Gq mediated signaling pathway suggesting the possible role of novel GPR142 agonists in therapy against type 2 diabetes.
Type 2 diabetes (T2D) has been established as a serious and chronic medical condition with clinical feature of insulin deficiency and the resultant pathologically high glucose level in blood. Among various approaches purposed for T2D treatment, small molecule like agonist for G-protein-coupled receptor 119 (GPR119) was suggested to regulate blood glucose level by stimulating pancreatic β-cells function. This study employed homology and threading modeling approach to predict the GPR119 structure and conducted the structure-based virtual screening (SBVS) to discover novel agonist for GPR119 signal activation. Although the SBVS approach concluded a total of 419 compounds, we selected only 10 compounds for validation based on their docking scores (threshold values were fixed between −16.23 and −10.00) with GPR119 active site. Further, biochemical pathway simulation was also conducted for T2D involving GPR119 and 10 screened compounds using system biology approach. However, we observed that only compound 1 (C23H29F3O6), with characteristics such as docking score of −16.227, MMGBSA value of −66.23, exhibiting attraction for GLN65, ARG71, and THR86 residues, and optimum concentration of 0.50 μM, has the potential to activate GPR119 signaling and subsequently regulated the glucose-dependent insulin secretion in blood. Hence, this novel compound 1 has vindicated its capacity for further development as a potential therapeutic agent in the treatment of T2D.
Multidrug-resistant Plasmodium is of major concern today. Effective vaccines or successful applications of RNAi-based strategies for the treatment of malaria are currently unavailable. An unexplored area in the field of malaria research is the development of DNA-targeting drugs that can specifically interact with parasitic DNA and introduce deleterious changes, leading to loss of vital genome function and parasite death.
7 December 2019 in Interdisciplinary Sciences: Computational Life Sciences